Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Prepaid Assets: 2019-2025

Historic Prepaid Assets for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $15.8 million.

  • IDEAYA Biosciences' Prepaid Assets rose 29.56% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 29.56%. This contributed to the annual value of $13.4 million for FY2024, which is 78.59% up from last year.
  • As of Q3 2025, IDEAYA Biosciences' Prepaid Assets stood at $15.8 million, which was down 0.65% from $15.9 million recorded in Q2 2025.
  • IDEAYA Biosciences' 5-year Prepaid Assets high stood at $15.9 million for Q2 2025, and its period low was $2.8 million during Q1 2022.
  • For the 3-year period, IDEAYA Biosciences' Prepaid Assets averaged around $11.0 million, with its median value being $11.5 million (2024).
  • Per our database at Business Quant, IDEAYA Biosciences' Prepaid Assets dropped by 23.48% in 2022 and then skyrocketed by 162.84% in 2024.
  • Quarterly analysis of 5 years shows IDEAYA Biosciences' Prepaid Assets stood at $3.1 million in 2021, then soared by 73.36% to $5.4 million in 2022, then spiked by 38.53% to $7.5 million in 2023, then spiked by 78.59% to $13.4 million in 2024, then grew by 29.56% to $15.8 million in 2025.
  • Its last three reported values are $15.8 million in Q3 2025, $15.9 million for Q2 2025, and $15.4 million during Q1 2025.